{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:37:34Z","timestamp":1785458254895,"version":"3.56.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective is to extract adverse event (AE) signals associated with molnupiravir from the FAERS database, thereby providing a reference for post-marketing monitoring of adverse events. Specifically, we extracted individual case safety reports (ICSRs) from the database, focusing on cases with COVID-19 indications and molnupiravir identified as the primary suspect drug. Descriptive analysis of the extracted data was performed, followed by four disproportionality analyses using the reporting odds ratio (ROR) method. These analyses were conducted across four levels, encompassing overall data, reports by health professionals, as well as age and gender differentiations, ensuring the robustness of the analysis results. In total, 116,576 ICSRs with COVID-19 indications and 2,285 ICSRs with molnupiravir as the primary suspect were extracted. Notably, after excluding cases with unknown age or gender, a higher proportion of molnupiravir-related ICSRs were observed among individuals aged 65\u00a0years and older (70.07%) and women (54.06%). The most frequently reported adverse events and AE signals were associated with gastrointestinal disorders, as well as skin and subcutaneous tissue disorders. Moreover, individuals aged 65\u00a0years and older exhibited a higher risk of cardiac disorders, hepatobiliary disorders, renal and urinary disorders, and vascular disorders. In conclusion, this study found molnupiravir demonstrated a lower risk of serious adverse events compared to other RNA antiviral drugs like remdesivir in patients under 65\u00a0years old. However, close monitoring of its safety is still necessary for elderly patients aged 65\u00a0years and above. Further studies are warranted to continuously assess the safety profile of molnupiravir as its usage increases, especially in high risk populations.<\/jats:p>","DOI":"10.3389\/fphar.2023.1253799","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:22:15Z","timestamp":1698747735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system"],"prefix":"10.3389","volume":"14","author":[{"given":"Yankun","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16017","article-title":"Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2","author":"Akhvlediani","year":"2023","journal-title":"Eur. J. Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jsps.2023.05.023","article-title":"The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and drug administration\u2019s adverse event reporting system","volume":"31","author":"Alsuhaibani","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e33676","DOI":"10.7759\/cureus.33676","article-title":"Efficacy and safety of favipiravir in treating COVID-19 patients: a meta-analysis of randomized control trials","volume":"15","author":"Batool","year":"2023","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100043","article-title":"Phase 2\/3 trial of molnupiravir for treatment of covid-19 in nonhospitalized adults","volume":"1","author":"Caraco","year":"2022","journal-title":"NEJM Evid."},{"key":"B6","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","volume-title":"StatPearls","author":"Cascella","year":"2023"},{"key":"B7","unstructured":"Coronavirus (COVID-19) | drugs2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.gastro.2020.03.065","article-title":"Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis","volume":"159","author":"Cheung","year":"2020","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0248009","DOI":"10.1371\/journal.pone.0248009","article-title":"Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes","volume":"16","author":"De Vito","year":"2021","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1080\/03007995.2022.2129801","article-title":"Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study","volume":"38","author":"De Vito","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"B11","unstructured":"Lagevrio: withdrawal of the marketing authorisation application2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/v14112560","article-title":"Molnupiravir: from hope to epic fail?","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cmi.2023.04.014","article-title":"Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Gao","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/ipc.0000000000000952","article-title":"A case of vasculitis-like skin eruption associated with COVID-19","volume":"28","author":"Geremia","year":"2020","journal-title":"Infect. Dis. Clin. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0234765","DOI":"10.1371\/journal.pone.0234765","article-title":"The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries","volume":"15","author":"Grant","year":"2020","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.30574\/gscbps.2022.18.3.0105","article-title":"A mini-review on clinical studies of Molnupiravir for COVID-19 conducted in selected Asian countries","volume":"18","author":"Joseph Mari","year":"2022","journal-title":"GSC Biol. Pharm. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/cts.13168","article-title":"Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database","volume":"15","author":"Jung","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(22)00644-2","article-title":"Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"23","author":"Khoo","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.cgh.2021.04.039","article-title":"Hepatobiliary adverse drug reactions associated with remdesivir: the WHO international pharmacovigilance study","volume":"19","author":"Kim","year":"2021","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s11845-022-03139-y","article-title":"Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review","volume":"192","author":"Mali","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/v15020384","article-title":"Molnupiravir and nirmatrelvir\/ritonavir: tolerability, safety, and adherence in a retrospective cohort study","volume":"15","author":"Mazzitelli","year":"2023","journal-title":"Viruses"},{"key":"B27","unstructured":"First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA2021"},{"key":"B28","unstructured":"Merck and ridgeback\u2019s molnupiravir, an investigational oral antiviral COVID-19 treatment, receives special approval for emergency in Japan - Merck.com2021"},{"key":"B29","unstructured":"FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR LAGEVRIO\u2122 (molnupiravir) CAPSULES2023"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/cts.13395","article-title":"A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19","volume":"15","author":"Nakamura","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"E969","DOI":"10.1503\/cmaj.220471","article-title":"Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis","volume":"194","author":"Pitre","year":"2022","journal-title":"CMAJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"21385","DOI":"10.1021\/acsomega.1c07095","article-title":"Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease","volume":"7","author":"Rabie","year":"2022","journal-title":"ACS Omega"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2001435","DOI":"10.1002\/advs.202001435","article-title":"A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study","volume":"7","author":"Ren","year":"2020","journal-title":"Adv. Sci. (Weinh)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40264-021-01091-x","article-title":"Remdesivir in the COVID-19 pandemic: an analysis of spontaneous reports in VigiBase during 2020","volume":"44","author":"Rocca","year":"2021","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1391583","DOI":"10.1155\/2020\/1391583","article-title":"Assessment of the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy","volume":"2020","author":"Shan","year":"2020","journal-title":"Comput. Math. Methods Med."},{"key":"B37","first-page":"414","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e00077721","DOI":"10.1590\/0102-311X00077721","article-title":"Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database","volume":"37","author":"Silva","year":"2021","journal-title":"Cad. Saude Publica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e31508","DOI":"10.7759\/cureus.31508","article-title":"Efficacy and safety of molnupiravir in mild COVID-19 patients in India","volume":"14","author":"Sinha","year":"2022","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"855496","DOI":"10.3389\/fimmu.2022.855496","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"key":"B41","unstructured":"Efficacy and safety of molnupiravir for the treatment of non-hospitalized adults with mild COVID-19: a randomized, open-label, parallel-group phase 3 trial\n            TippabhotlaS. K.\n            LahiriD. S.\n            KandiC.\n          2022"},{"key":"B42","volume-title":"Common Terminology Criteria for adverse events (CTCAE)","year":"2017"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hed.26269","article-title":"Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study","volume":"42","author":"Vaira","year":"2020","journal-title":"Head. Neck"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-022-01152-z","article-title":"Clinically relevant interactions between ritonavir-boosted nirmatrelvir and concomitant antiseizure medications: implications for the management of COVID-19 in patients with epilepsy","volume":"61","author":"Wanounou","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"B46","unstructured":"WHO coronavirus (COVID-19) dashboard2023"},{"key":"B47","doi-asserted-by":"publisher","first-page":"692828","DOI":"10.3389\/fphar.2022.692828","article-title":"Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"939573","DOI":"10.3389\/fphar.2022.939573","article-title":"Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B49","article-title":"Human safety, tolerability, and pharmacokinetics of a novel broad-spectrum oral antiviral compound, molnupiravir, with activity against SARS-CoV-2","author":"Painter","year":"2020","journal-title":"medrxiv"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1253799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:22:20Z","timestamp":1698747740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1253799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1253799"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1253799","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"article-number":"1253799"}}